I'm LongbridgeAI, I can summarize articles.JPMorgan Chase faces a regulatory dispute with the Federal Reserve over capital rules, potentially impacting $13 billion in capital relief. This amount equals approximately 61% of the bank's second-quarter net income of $21.2 billion. The Fed's proposal to change wholesale funding treatment favors trading-heavy rivals, though overall capital requirements would still decrease. JPMorgan argues the current formula is unfair, while supporters claim it improves risk measurement. The outcome significantly affects shareholder value and the bank's premium valuation.
JPMorgan Chase , America's biggest bank by assets, traded at $353 Thursday as a regulatory fight put $13 billion of potential capital relief on the line. Reuters, citing the bank's public June comment letter, reported that changing the treatment of short-term wholesale funding would shrink JPMorgan's expected benefit from the Federal Reserve's broader capital overhaul. That is not regulatory pocket change. It is capital that could work for shareholders.
The Federal Reserve proposal would change how wholesale funding is measured and weighted when calculating surcharges for global systemically important banks. JPMorgan says the formula hands an advantage to trading-heavy rivals. Supporters argue it measures risk more accurately. The overall plan still cuts capital requirements. The real showdown is over which banks walk away with the biggest prize.
JPMorgan generated second-quarter net income of $21.2 billion, making the disputed $13 billion equal to roughly 61% of one quarter's profit. The valuation chart raises the bar further: the $353 share price stands 12.25% above the $314.49 GF Value estimate. Investors are already paying a premium, so every dollar of capital reliefand how management deploys itmatters.